Carisbamate has been investigated in Alcohol Abuse, Substance Abuse, and Alcohol Dependence.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | Carisbamate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Carisbamate. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Carisbamate. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Carisbamate. |
| Hydrocodone | Carisbamate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Carisbamate. |
| Magnesium sulfate | The therapeutic efficacy of Carisbamate can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Carisbamate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Carisbamate may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Carisbamate. |
| Mirtazapine | Carisbamate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Carisbamate. |
| Orphenadrine | Carisbamate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Carisbamate may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Carisbamate. |
| Pramipexole | Carisbamate may increase the sedative activities of Pramipexole. |
| Ropinirole | Carisbamate may increase the sedative activities of Ropinirole. |
| Rotigotine | Carisbamate may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Carisbamate. |
| Sodium oxybate | Carisbamate may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | Carisbamate may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Carisbamate. |
| Thalidomide | Carisbamate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Carisbamate may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Mefloquine | The therapeutic efficacy of Carisbamate can be decreased when used in combination with Mefloquine. |
| Mianserin | The therapeutic efficacy of Carisbamate can be decreased when used in combination with Mianserin. |
| Orlistat | Orlistat can cause a decrease in the absorption of Carisbamate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Topotecan | Carisbamate may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Carisbamate. |
| Tetracosactide | The risk or severity of liver damage can be increased when Tetracosactide is combined with Carisbamate. |
| Ethanol | Carisbamate may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Carisbamate may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Carisbamate. |
| Fluvoxamine | The risk or severity of adverse effects can be increased when Carisbamate is combined with Fluvoxamine. |
| Citalopram | The risk or severity of adverse effects can be increased when Carisbamate is combined with Citalopram. |
| Duloxetine | The risk or severity of adverse effects can be increased when Carisbamate is combined with Duloxetine. |
| Trazodone | The risk or severity of adverse effects can be increased when Carisbamate is combined with Trazodone. |
| Paroxetine | The risk or severity of adverse effects can be increased when Carisbamate is combined with Paroxetine. |
| Sertraline | The risk or severity of adverse effects can be increased when Carisbamate is combined with Sertraline. |
| Sibutramine | The risk or severity of adverse effects can be increased when Carisbamate is combined with Sibutramine. |
| Nefazodone | The risk or severity of adverse effects can be increased when Carisbamate is combined with Nefazodone. |
| Escitalopram | The risk or severity of adverse effects can be increased when Carisbamate is combined with Escitalopram. |
| Zimelidine | The risk or severity of adverse effects can be increased when Carisbamate is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when Carisbamate is combined with Dapoxetine. |
| Milnacipran | The risk or severity of adverse effects can be increased when Carisbamate is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of adverse effects can be increased when Carisbamate is combined with Desvenlafaxine. |
| Seproxetine | The risk or severity of adverse effects can be increased when Carisbamate is combined with Seproxetine. |
| Indalpine | The risk or severity of adverse effects can be increased when Carisbamate is combined with Indalpine. |
| Ritanserin | The risk or severity of adverse effects can be increased when Carisbamate is combined with Ritanserin. |
| Alaproclate | The risk or severity of adverse effects can be increased when Carisbamate is combined with Alaproclate. |
| Amitriptyline | The risk or severity of CNS depression can be increased when Amitriptyline is combined with Carisbamate. |
| Cyproheptadine | The risk or severity of CNS depression can be increased when Cyproheptadine is combined with Carisbamate. |
| Imipramine | The risk or severity of CNS depression can be increased when Imipramine is combined with Carisbamate. |
| Nortriptyline | The risk or severity of CNS depression can be increased when Nortriptyline is combined with Carisbamate. |
| Amoxapine | The risk or severity of CNS depression can be increased when Amoxapine is combined with Carisbamate. |
| Propiomazine | The risk or severity of CNS depression can be increased when Propiomazine is combined with Carisbamate. |
| Cocaine | The risk or severity of methemoglobinemia can be increased when Carisbamate is combined with Cocaine. |
| Quinidine | The therapeutic efficacy of Carisbamate can be decreased when used in combination with Quinidine. |
| Maprotiline | The risk or severity of CNS depression can be increased when Maprotiline is combined with Carisbamate. |
| Doxepin | The risk or severity of CNS depression can be increased when Doxepin is combined with Carisbamate. |
| Desipramine | The risk or severity of CNS depression can be increased when Desipramine is combined with Carisbamate. |
| Pizotifen | The risk or severity of CNS depression can be increased when Pizotifen is combined with Carisbamate. |
| Dosulepin | The risk or severity of CNS depression can be increased when Dosulepin is combined with Carisbamate. |
| Zopiclone | The risk or severity of adverse effects can be increased when Carisbamate is combined with Zopiclone. |
| Botulinum toxin type B | The risk or severity of CNS depression can be increased when Botulinum toxin type B is combined with Carisbamate. |
| Botulinum toxin type A | The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Carisbamate. |
| Tryptophan | The risk or severity of CNS depression can be increased when Tryptophan is combined with Carisbamate. |
| Baclofen | Baclofen may increase the central nervous system depressant (CNS depressant) activities of Carisbamate. |
| Lorazepam | The risk or severity of CNS depression can be increased when Lorazepam is combined with Carisbamate. |
| Ethchlorvynol | The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Carisbamate. |
| Succinylcholine | The risk or severity of CNS depression can be increased when Succinylcholine is combined with Carisbamate. |
| Reserpine | The risk or severity of CNS depression can be increased when Reserpine is combined with Carisbamate. |
| Eletriptan | The risk or severity of CNS depression can be increased when Eletriptan is combined with Carisbamate. |
| Enflurane | The risk or severity of CNS depression can be increased when Enflurane is combined with Carisbamate. |
| Temazepam | The risk or severity of CNS depression can be increased when Temazepam is combined with Carisbamate. |
| Reboxetine | The risk or severity of CNS depression can be increased when Reboxetine is combined with Carisbamate. |
| Butabarbital | The risk or severity of CNS depression can be increased when Butabarbital is combined with Carisbamate. |
| Butalbital | The risk or severity of CNS depression can be increased when Butalbital is combined with Carisbamate. |
| Methysergide | The risk or severity of CNS depression can be increased when Methysergide is combined with Carisbamate. |
| Cabergoline | The risk or severity of CNS depression can be increased when Cabergoline is combined with Carisbamate. |
| Phenytoin | The risk or severity of CNS depression can be increased when Phenytoin is combined with Carisbamate. |
| Topiramate | The risk or severity of CNS depression can be increased when Topiramate is combined with Carisbamate. |
| Clemastine | The risk or severity of CNS depression can be increased when Clemastine is combined with Carisbamate. |
| Venlafaxine | The risk or severity of CNS depression can be increased when Venlafaxine is combined with Carisbamate. |
| Etomidate | The risk or severity of CNS depression can be increased when Etomidate is combined with Carisbamate. |
| Morphine | The risk or severity of CNS depression can be increased when Morphine is combined with Carisbamate. |
| Talbutal | The risk or severity of CNS depression can be increased when Talbutal is combined with Carisbamate. |
| Pentobarbital | The risk or severity of CNS depression can be increased when Pentobarbital is combined with Carisbamate. |
| Valproic acid | The risk or severity of CNS depression can be increased when Valproic acid is combined with Carisbamate. |
| Zolmitriptan | The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Carisbamate. |
| Codeine | The risk or severity of CNS depression can be increased when Codeine is combined with Carisbamate. |
| Dihydroergotamine | The risk or severity of CNS depression can be increased when Dihydroergotamine is combined with Carisbamate. |
| Tolcapone | The risk or severity of CNS depression can be increased when Tolcapone is combined with Carisbamate. |
| Hydromorphone | The risk or severity of CNS depression can be increased when Hydromorphone is combined with Carisbamate. |
| Olanzapine | The risk or severity of CNS depression can be increased when Olanzapine is combined with Carisbamate. |
| Cetirizine | The risk or severity of CNS depression can be increased when Cetirizine is combined with Carisbamate. |
| Protriptyline | The risk or severity of CNS depression can be increased when Protriptyline is combined with Carisbamate. |
| Trimethadione | The risk or severity of CNS depression can be increased when Trimethadione is combined with Carisbamate. |
| Clobazam | The risk or severity of sedation, somnolence, and CNS depression can be increased when Clobazam is combined with Carisbamate. |
| Chlorzoxazone | The risk or severity of CNS depression can be increased when Chlorzoxazone is combined with Carisbamate. |